Structure Therapeutics Inc. Sponsored ADR (GPCR)
(Delayed Data from NSDQ)
$42.76 USD
+0.93 (2.22%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $42.71 -0.05 (-0.12%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GPCR 42.76 +0.93(2.22%)
Will GPCR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GPCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GPCR
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
Structure Therapeutics (GPCR) Stock Up 9% This Week: Here's Why
GPCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
IPO Round Up of First Half of 2023
Other News for GPCR
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
Jefferies Reaffirms Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Maintained Buy Rating: Overreaction to Sell-off Undervalues Structure Therapeutics’ Market Potential
Lilly, Novo Nordisk to dominate weight loss therapy market: SA Investing Summit
Structure Therapeutics: Yet Another Potential GLP-1 Entrant